CAR Treg-cell therapy (Orchard Therapeutics)

N/A

Report date: 2025/01/26 19:05:41

Base Information

Drug NameCAR Treg-cell therapy (Orchard Therapeutics)
Drug Alias NameHSC-CAR Treg gene therapy (Orchard Therapeutics)HSC-derived Tregs expressing CAR (Orchard Therapeutics)
ClassificationCell and gene therapy > Cell therapy > Stem cell therapy > Hematopoietic stem cells therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionImmunosuppressants
TargetsUpdating
Therapy Area/IndicationsAutoimmune DiseasesDiabetes Mellitus, Type 1Arthritis, Rheumatoid
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited Kingdom
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesOrchard Therapeutics Plc
China Registration ClassN/A

Develop Information

Active CompaniesOrchard Therapeutics Plc
Inactive CompaniesN/A
Active IndicationsAutoimmune DiseasesDiabetes Mellitus, Type 1Arthritis, Rheumatoid
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A